Clinical trial
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women…
NCT00143390 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00143390 |
|---|---|
| Title | Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer |
| Official title | A Randomized, Double-Blind, Controlled Study Of Exemestane (Aromasin) Vs Anastrozole (Arimidex) As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | exemestane, anastrozole |
| Enrollment | 298 |
| Start date | Apr 1, 2005 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Sep 2, 2005 |
| Last update posted | Jan 25, 2012 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: